Evolution of extended-spectrum β-lactamases in a MutS-deficient Pseudomonas aeruginosa hypermutator [11]

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 4, 2006, Pages 905-907

  Driffield, Kiersten L ^a   Bostock, Julieanne M ^a   Miller, Keith ^a   O'Neill, Alexander J ^a   Hobbs, Joanne K ^a   Chopra, Ian ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Ceftazidime; Mutation; Resistance

Indexed keywords

AMINO ACID; BACTERIAL ENZYME; BETA LACTAMASE AMPC; CEFTAZIDIME; CEPHALOSPORIN; EXTENDED SPECTRUM BETA LACTAMASE; STREPTOMYCIN;

AMINO ACID SUBSTITUTION; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIUM CONJUGATION; BACTERIUM CULTURE; BACTERIUM MUTANT; CONTROLLED STUDY; DRUG HYDROLYSIS; ENZYME ACTIVE SITE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; HUMAN; LETTER; MINIMUM INHIBITORY CONCENTRATION; MISMATCH REPAIR; MUTATION RATE; NONHUMAN; PLASMID; POINT MUTATION; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BETA-LACTAMS; CEFTAZIDIME; CEPHALOSPORIN RESISTANCE; EVOLUTION, MOLECULAR; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; MUTS DNA MISMATCH-BINDING PROTEIN; PSEUDOMONAS AERUGINOSA;

EID: 33748711621     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl324     Document Type: Letter

References (6)

1. Ellington MJ, Livermore DM, Pitt TL et al. Accelerated development of TEM-29 extended-spectrum β-lactamase from TEM-1 in hypermutable, mutS, Escherichia coli. In: Programs and Abstracts of the Fifteenth European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, 2005. Abstract P475. Clin Microbiol Infect 2005; 11 Suppl 2: 123.
2. Macia MD, Blanquer D, Togores B et al. Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob Agents Chemother 2005; 49: 3382-6.
3. Oliver A, Levin BR, Juan C et al. Hypermutation and the preexistence of antibiotic-resistant Pseudomonas aeruginosa mutants: Implications for susceptibility testing and treatment of chronic infections. Antimicrob Agents Chemother 2004; 48: 4226-33.
4. Danel F, Hall LM, Livermore DM. Laboratory mutants of OXA-10 β-lactamase giving ceftazidime resistance in Pseudomonas aeruginosa. J Antimicrob Chemother 1999; 43: 339-44.
5. Vuye A, Verschraegen G, Claeys G. Plasmid-mediated β-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli resistant to ceftazidime. Antimicrob Agents Chemother 1989; 33: 757-61.
6. Zamayova M, Siebor E, Pechinot A et al. Survey of Enterobacteriaceae producing extended-spectrum β-lactamases in a Slovak hospital: dominance of SHV-2a and characterization of TEM-132. Antimicrob Agents Chemother 2005; 49: 3066-9.